Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory R Bean

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Applied Immunohistochemistry & Molecular Morphology : AIMM|June 11, 2026
HER2 In Situ Hybridization: Validation and Implementation of Brightfield Assay in a US Academic Pathology LaboratoryMegan L Troxell, Alex M Dussaq, Joanna Solarewicz, et al.
Nature Cancer|December 30, 2021
Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts responseKatherine L McNamara, Jennifer L Caswell-Jin, Rohan Joshi, et al.
Histopathology|December 28, 2025
Genetic and immunohistochemical studies identify recurrent ACTB mutations and PTEN alterations in tubular adenomas of the breastHnin Ingyin, James P Solomon, Yuewei Li, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 27, 2017
Genomic profiling of breast secretory carcinomas reveals distinct genetics from other breast cancers and similarity to mammary analog secretory carcinomasGregor Krings, Nancy M Joseph, Gregory R Bean, et al.
Cell Death & Disease|October 14, 2016
A metabolic synthetic lethal strategy with arginine deprivation and chloroquine leads to cell death in ASS1-deficient sarcomasGregory R Bean, Jeff C Kremer, Bethany C Prudner, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 16, 2007
Hypermethylation of the breast cancer-associated gene 1 promoter does not predict cytologic atypia or correlate with surrogate end points of breast cancer riskGregory R Bean, Catherine Ibarra Drendall, Vanessa K Goldenberg, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 13, 2005
Retinoic acid receptor-beta2 promoter methylation in random periareolar fine needle aspirationGregory R Bean, Victoria Scott, Lisa Yee, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 19, 2008
ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemopreventionJoseph C Baker, Julie H Ostrander, Siya Lem, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 5, 2009
CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesisShauna N Vasilatos, Gloria Broadwater, William T Barry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2007
Morphologically normal-appearing mammary epithelial cells obtained from high-risk women exhibit methylation silencing of INK4a/ARFGregory R Bean, Andrew D Bryson, Patrick G Pilie, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Applied Immunohistochemistry & Molecular Morphology : AIMM|June 11, 2026
HER2 In Situ Hybridization: Validation and Implementation of Brightfield Assay in a US Academic Pathology LaboratoryMegan L Troxell, Alex M Dussaq, Joanna Solarewicz, et al.
Nature Cancer|December 30, 2021
Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts responseKatherine L McNamara, Jennifer L Caswell-Jin, Rohan Joshi, et al.
Histopathology|December 28, 2025
Genetic and immunohistochemical studies identify recurrent ACTB mutations and PTEN alterations in tubular adenomas of the breastHnin Ingyin, James P Solomon, Yuewei Li, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 27, 2017
Genomic profiling of breast secretory carcinomas reveals distinct genetics from other breast cancers and similarity to mammary analog secretory carcinomasGregor Krings, Nancy M Joseph, Gregory R Bean, et al.
Cell Death & Disease|October 14, 2016
A metabolic synthetic lethal strategy with arginine deprivation and chloroquine leads to cell death in ASS1-deficient sarcomasGregory R Bean, Jeff C Kremer, Bethany C Prudner, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 16, 2007
Hypermethylation of the breast cancer-associated gene 1 promoter does not predict cytologic atypia or correlate with surrogate end points of breast cancer riskGregory R Bean, Catherine Ibarra Drendall, Vanessa K Goldenberg, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 13, 2005
Retinoic acid receptor-beta2 promoter methylation in random periareolar fine needle aspirationGregory R Bean, Victoria Scott, Lisa Yee, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 19, 2008
ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemopreventionJoseph C Baker, Julie H Ostrander, Siya Lem, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 5, 2009
CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesisShauna N Vasilatos, Gloria Broadwater, William T Barry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2007
Morphologically normal-appearing mammary epithelial cells obtained from high-risk women exhibit methylation silencing of INK4a/ARFGregory R Bean, Andrew D Bryson, Patrick G Pilie, et al.
Pageof 7